Company Profile
Frazier Life Sciences is a healthcare investment firm specializing in the discovery, development, and commercialization of innovative biopharmaceuticals. The firm manages both venture and public funds, investing in private and publicly traded companies across all stages of therapeutics development. Frazier is known for its hands-on approach to company building, having formed over 30 companies since 2005 and partnering with entrepreneurs to accelerate the advancement of new therapies for patients.
The firm’s venture funds primarily focus on company creation, seed, Series A, and Series B investments, while its public funds support small- and mid-cap biotech companies through IPOs, follow-ons, PIPEs, and open market financings. Frazier Life Sciences has a strong track record, with its portfolio generating over 40 FDA-approved therapeutics since 2010 and completing more than 60 IPOs or strategic acquisitions.
Headquartered in Palo Alto, California, Frazier Life Sciences invests globally and maintains a diversified portfolio across therapeutic areas. The firm’s latest venture fund, Frazier Life Sciences XII, raised over $1.3 billion, underscoring its continued leadership in the biotech venture capital space. Frazier’s investments span oncology, fibrosis, rare diseases, gastrointestinal disorders, genetic diseases, neurology, immunology, infectious diseases, metabolic diseases, cardiovascular, and dermatology.
News & Signals (0)
No linked news activity found for this company.